Primary debulking surgery and neoadjuvant chemotherapy in the treatment of advanced epithelial ovarian carcinoma

详细信息    查看全文

• 作者：Shelly M. Seward ; Ira Winer
• 关键词：Ovarian cancer ; Primary debulking surgery ; Neoadjuvant chemotherapy
• 刊名：Cancer and Metastasis Reviews
• 出版年：2015
• 出版时间：March 2015
• 年：2015
• 卷：34
• 期：1
• 页码：5-10
• 全文大小：3,557 KB
• 参考文献：1. Cancer Facts & Figures. (2014). Atlanta: / American Cancer Society; 2014.
  2. Buys, S.S., Partridge, E., Black, A., Johnson, C.C., Lamerato, I., Isaacs, C. (2011). Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. / Journal of the American Medical Association. 2295-03.
  3. Menon, U.G-M.A., Hallett, R., Ryan, A., Burnell, M., Sharma, A., Lewis, S., Davies, S., Philpott, S., Lopes, A., Godfrey, K., Oram, D., Herod, J., Williamson, K., Seif, MW., Scott, I., Mould, T., Woolas, R., Murdoch, J., Dobbs, S., Amso, NN., Leeson, S., Cruickshank, D., et al. (2009). Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). / Lancet Oncology. 327-0.
  4. Kurman, R.J., Shih, I.M. (2011). Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—shifting the paradigm. / Human Pathology. 918-1.
  5. Griffiths, C. (1975). Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. / National Cancer Institute Monographs. 101-.
  6. Hoskins, WJ, Bundy, BN, Thigpen, JT, Omura, GA (1992) The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a gynecologic oncology group study. Gynecologic Oncology 47: pp. 159-62 CrossRef
  7. Hoskins, W.J., Creasman, M.W., Grady, M.F., Homesley, H.D., Creasman, W.T., Berman, M., Ball, H., Berek, J.S. (1994). The effect of tumor diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. / American Journal of Obstetrics and Gynecology. 974-.
  8. Fader, AN, Rose, P (2007) Role of surgery in ovarian carcinoma. Journal of Clinical Oncology 25: pp. 2873-83 CrossRef
  9. Bristow, RE, Tomacruz, R, Armstrong, DK, Trimble, EL, Montz, FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. Journal of Clinical Oncology 20: pp. 1248-59 CrossRef
  10. Chang, SJ, Bristow, R, Ryu, HS (2012) Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in ovarian cancer. Annals of Surgical Oncology 19: pp. 4059-67 CrossRef
  11. Winter, WE, Maxwell, G, Tian, C, Carlson, JW, Ozols, RF, Rose, PG, Markman, M, Armstrong, DK, Muggia, F, McGuire, WP (2007) Prognostic factors for stage III epithelial ovarian cancer: a gynecologic oncology study group. Journal of Clincial Oncology 25: pp. 3621-7 CrossRef
  12. Bois, A, Reuss, A, Pujade-Lauraine, E, Harter, P, Ray-Coquard, I, Pfisterer, J (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials. Cancer 115: pp. 1234-44 CrossRef
  13. Elattar, A., Bryant, A., Winter-Roach, B.A., Hatem, M., Naik, R. (2011). Optimal primary surgical treatment for advanced epithelial ovarian cancer (Review). / Cochrane Database Systematic Review. 2011.
  14. Vergote, IB, Wever, I, Decloedt, J, Tjalma, W, Gramberen, M, Dam, P (2000) Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer. Seminars in Oncology 27: pp. 31-6
  15. Schwartz, PE, Chambers, JT, Makuch, R (1994) Neoadjuvant chemotherapy for advanced ovarian cancer. Gynecologic Oncology 53: pp. 33-7 CrossRef
  16. Bristow, R, Chi, DS (2006) Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecologic Oncology 103: pp. 1070-6 CrossRef
  17. Schorge, JO, Clark, R, Lee, SI, Penson, RT (2014) Primary debulking surgery for advanced ovarian cancer: are you a believer or dissenter?. Gynecologic O
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Oncology
  Cancer Research
  
• 出版者：Springer Netherlands
• ISSN：1573-7233

文摘

Surgery and chemotherapy are the standard of care for epithelial ovarian cancer, and it is well established that survival outcomes are improved when the surgery results in no or optimal (less than 1?cm) residual disease. However, for patients with bulky disease that may require extensive or radical procedures to accomplish this goal, the use of neoadjuvant chemotherapy followed by interval debulking surgery to simplify the surgery and minimize morbidity has been suggested. Arguably, this is only ideal if this process produces survival outcomes equivalent to those of primary debulking surgery. The purpose of this article is to review the data surrounding this controversial topic.